DDInter704 DDInter1435
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Everolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Everolimus {u} (Compound) treats {v} (Disease) kidney cancer
Everolimus {u} (Compound) binds {v} (Gene) FKBP1A
Everolimus {u} (Compound) upregulates {v} (Gene) USP20
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2D6 Inhibitors
Everolimus {u} (Compound) downregulates {v} (Gene) ATF1
Everolimus {u} (Compound) causes {v} (Side Effect) Pericardial effusion
Everolimus (Compound) resembles Pimecrolimus (Compound)
Everolimus (Compound) resembles Temsirolimus (Compound)
Everolimus (Compound) treats kidney cancer (Disease)
Everolimus (Compound) binds FKBP1A (Gene)
Everolimus (Compound) upregulates USP20 (Gene)
Everolimus (Compound) is included by Cytochrome P450 2D6 Inhibitors (Pharmacologic Class)
Everolimus (Compound) downregulates ATF1 (Gene)
Everolimus (Compound) causes Pericardial effusion (Side Effect)